129 related articles for article (PubMed ID: 2166504)
1. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Shaw MK; Newton RS; Sliskovic DR; Roth BD; Ferguson E; Krause BR
Biochem Biophys Res Commun; 1990 Jul; 170(2):726-34. PubMed ID: 2166504
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.
Parker RA; Clark RW; Sit SY; Lanier TL; Grosso RA; Wright JJ
J Lipid Res; 1990 Jul; 31(7):1271-82. PubMed ID: 2401858
[TBL] [Abstract][Full Text] [Related]
3. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
Bocan TM; Ferguson E; McNally W; Uhlendorf PD; Bak Mueller S; Dehart P; Sliskovic DR; Roth BD; Krause BR; Newton RS
Biochim Biophys Acta; 1992 Jan; 1123(2):133-44. PubMed ID: 1739744
[TBL] [Abstract][Full Text] [Related]
4. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
Kocarek TA; Reddy AB
Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
[TBL] [Abstract][Full Text] [Related]
5. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Dansette PM; Jaoen M; Pons C
Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
[TBL] [Abstract][Full Text] [Related]
7. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Hagiwara M; Kataoka K; Arimochi H; Kuwahara T; Nakayama H; Ohnishi Y
World J Gastroenterol; 2005 Feb; 11(7):1040-3. PubMed ID: 15742411
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cholesterol synthesis ex vivo and in vivo by fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Experientia; 1995 Mar; 51(3):223-6. PubMed ID: 7698284
[TBL] [Abstract][Full Text] [Related]
11. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
12. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y
J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454
[TBL] [Abstract][Full Text] [Related]
13. Species differences in the inhibiting effect of fluvastatin, a new inhibitor of HMG-CoA reductase, on cholesterol biosynthesis.
Yamamoto A; Itoh S; Hoshi K; Ichihara K
Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):325-34. PubMed ID: 7712108
[TBL] [Abstract][Full Text] [Related]
14. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Qin W; Infante J; Wang SR; Infante R
Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
[TBL] [Abstract][Full Text] [Related]
15. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Kah J; Wüstenberg A; Keller AD; Sirma H; Montalbano R; Ocker M; Volz T; Dandri M; Tiegs G; Sass G
Oncol Rep; 2012 Sep; 28(3):1077-83. PubMed ID: 22710979
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Rosenson RS; Tangney CC; Schaefer EJ
Atherosclerosis; 2001 Apr; 155(2):463-6. PubMed ID: 11254918
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Turner NA; Midgley L; O'Regan DJ; Porter KE
J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
19. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
[TBL] [Abstract][Full Text] [Related]
20. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Satoh K; Ichihara K
J Cardiovasc Pharmacol; 2000 Feb; 35(2):256-62. PubMed ID: 10672858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
